PSCH
Invesco S&P SmallCap Health Care ETF
Invesco S&P SmallCap Health Care Portfolio is an exchange traded fund incorporated in the USA. The Fund's objective is to seeks investment results that correspond (before fees and expenses) generally to the price and yield performance of the S&P SmallCap 600 Capped Health Care Index.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 154.8 M
ASSETS UNDER MGMT
29 bp
EXPENSES
Fund Basics
| Inception date | Apr 07, 2010 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| CORCEPT THERAPEUTICS INC | 5.2 % |
| TELEFLEX INC | 3.6 % |
| RADNET INC | 3.4 % |
| ALKERMES PLC | 3.2 % |
| GLAUKOS CORP | 3.1 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 3.1 % |
| MERIT MEDICAL SYSTEMS INC | 3.1 % |
| TG THERAPEUTICS INC | 3.1 % |
| KRYSTAL BIOTECH, INC. | 2.9 % |
| WAYSTAR HOLDING CORP | 2.8 % |
Constituent Breakdown
| Number of holdings | 69 |
| Herfindahl-Hirschman Index | 207 |
| Wgt avg mkt cap (mns) | $3,209 |
| Large cap (>$10bn) | 64.1% |
| Mid cap ($2-10bn) | 30.3% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 94.4% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 91.2 % |
 |
IRELAND | 3.2 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 1.3% | 8.1% | 4.3% | 0.3% | -6.5% | 6.8% | -- | 11.0% |
| Dividend Yield | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.0% | -- | 0.2% |
| Total Returns | 1.3% | 8.1% | 4.4% | 0.4% | -6.4% | 6.8% | -- | 11.2% | Ann. Volatility | 22.2% | 21.0% | 22.5% | 21.9% | 23.0% | 23.7% | -- | 22.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.15 | 46% |
| MSCI EAFE | 0.89 | 38% |
| MSCI Emg Mkts | 0.59 | 27% |
Liquidity Measures
| Avg. volume (000) | 11 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.26% |
Technical Indicators
| 30d moving avg. (EMA) | $44.35 |
| Relative strength (RSI) | 54 |
| MACD/Signal | 0.38/0.52 |
| Bollinger Bands (Upper/Lower) | $45.77/$44.11 |
| Short interest (% of AUM) | 0.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PSCH |
Expenses vs. PSCH |
ALTAR Score™ vs. PSCH |
|---|---|---|---|---|
| XHE | State Street SPDR S&P Health Care Equipment ETF | 21.5% | +6 bp | +1.2% |
| RZG | Invesco S&P Smallcap 600 Pure Growth ETF | 21.3% | +6 bp | +1.8% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 19.7% | +27 bp | -0.9% |
| CAFG | Pacer US Small Cap Cash Cows Growth Leaders ETF | 16.9% | +30 bp | +2.2% |
| XHS | State Street SPDR S&P Health Care Services ETF | 14.8% | +6 bp | +1.4% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 14.5% | +6 bp | -3.6% |
| PJP | Invesco Pharmaceuticals ETF | 13.4% | +28 bp | +5.1% |
| XBI | State Street SPDR S&P Biotech ETF | 13.4% | +6 bp | -2.8% |
| IBRN | iShares Neuroscience and Healthcare ETF | 13.2% | +18 bp | -2.7% |
| IJT | iShares S&P Small-Cap 600 Growth ETF | 11.7% | -11 bp | +1.8% |
Risk and Returns: PSCH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/29/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
2.7%
ALTAR SCORE™
12nd
PERCENTILE
AVOID
ETFRC RATING
There are 1,401 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. PSCH's ALTAR Score™ is approximately -1.2 standard
deviations above the category average. This places PSCH in the 12nd percentile
among funds in the category.
Sell-Side Consensus
$57.72
PRICE TARGET
+27.5%
UPSIDE